BLex 404 with azacitidine for higher-risk MDS and CMML
Part of Blood & lymphatic clinical trials.
This study tests an investigational oral liquid called BLEX 404 taken together with a standard drug, azacitidine, for people with higher-risk MDS or CMML. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years old or older.
- You must be diagnosed with intermediate-1, intermediate-2, or high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).
- You must not have received any prior treatment for MDS or CMML and be about to start a standard medicine called azacitidine for the first time.
- You need to have adequate liver and kidney function.
- You must not have a history of allergic reactions to mushrooms.
- You must not have active hepatitis B, C, or HIV infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for people with myelodysplastic syndrome (MDS), a blood disorder. The drug aims to slow the disease and improve blood counts, and might be an option for patients who haven't responded to other treatments.
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This trial tests whether adding bexmarilimab to standard azacitidine treatment helps people with higher-risk myelodysplastic syndromes (MDS), a type of blood cancer. It compares this combination to azacitidine plus a placebo to see which is more effective.
This study tests a new drug (PBSS1113) combined with azacitidine for people with certain blood cancers (AML or high-risk MDS). The goal is to see if the combination is safe and effective.
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
Hear when a new Myelodysplastic Syndrome (MDS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.